Welcome to LookChem.com Sign In|Join Free
  • or
methyl trans-4-(4-chlorophenyl)cyclohexane-1-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

128208-09-3

Post Buying Request

128208-09-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

128208-09-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 128208-09-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,2,0 and 8 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 128208-09:
(8*1)+(7*2)+(6*8)+(5*2)+(4*0)+(3*8)+(2*0)+(1*9)=113
113 % 10 = 3
So 128208-09-3 is a valid CAS Registry Number.

128208-09-3Relevant academic research and scientific papers

Synthesis and biological evaluation of 4-(4-chlorophenyl)cyclohexane carbohydrazide derivatives as anti-bacterial agents

Venkatasatyanarayana,Lakshmana Rao,Thirumala Chary,Ram,Balram,Laxminarayana

, p. 2267 - 2272 (2015)

The present paper describes the synthesis and antibacterial activity of novel hydrazone derivatives 4a-s derived from 4-(4-chlorophenyl)-cyclohexane carboxylic acid. All the ninteen newly synthesized novel hydrazone derivatives 4a-s were evaluated for their in vitro antibacterial activity against Staphylococcus aureus and S. pyogenes (Gram-positive bacteria) and Escherichia coli and Pseudomonas aeruginosa (Gram-negative bacteria). Antibacterial activity data revealed that the basic scaffold with R = nitrogen heterocyclic ring such as pyridine, quinoline, imidazole and indole showed significant antibacterial activity (excellent activity), whereas the hetrocyclic ring like benzo[b]furan, furan, thiophene moiety showed good antibacterial activity.

A pharmaceutical intermediate 4 - (4 - chlorophenyl) cyclohexyl -1 - formic acid

-

Paragraph 0035; 0042; 0043, (2017/04/19)

The invention belongs to the field of preparation of drug intermediates and particularly relates to a synthesis method of a drug intermediate 4-(4-chlorphenyl) cyclohexyl-1-formic acid. The method comprises the following steps: firstly reacting a compound I with R2SO2Cl in the presence of an acid-binding agent to obtain a compound II; carrying out catalytic coupling reaction on the compound II and a Grignard reagent 4-chlorphenyl magnesium halide under the action of a catalyst to obtain a compound III; and finally hydrolyzing the compound III in alkali liquor to obtain a target product 4-(4-chlorphenyl) cyclohexyl-1-formic acid. According to the synthesis method, all steps in a reaction route are exclusive reactions; and ortho-position and meta-position problems in friedel-crafts reaction are overcome, so that the utilization rate of raw materials is high; the total yield is high; and the cost is low. A main body structure is constructed by a coupling technique, so that the problem that hydrolysate which is formed after a lot of lewis acid used in the friedel-crafts reaction is hydrolyzed needs to be subjected to special treatment is overcome; the method is environment-friendly; and industrialized production is facilitated.

Synthesis, characterization and antimicrobial evaluation of (E)-4-(substitutedphenyl)-N′-(1-phenylethylidene)cyclohexane carbohydrazide derivatives

Venkatasatyanarayana,Lakshmana Rao,Laxminarayana,Thirumala Chary

, p. 718 - 723 (2017/01/18)

Encouraged by the various biological activities associated with hydrazone derivatives, the present paper describes the synthesis, characterization and antimicrobial evaluation of (E)-4-(substituted phenyl)-N′-(1-phenylethylidene) cyclohexanecarbohydrazide

TRICYCLIC HETEROCYCLIC COMPOUNDS

-

Page/Page column 171-172, (2011/06/16)

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 128208-09-3